Clinical trials: Carcinoma, Bronchogenic
Non Small Cell Lung Cancer
Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer
The purpose of this research study is to evaluate a blood test to measure circulating tumor DNA (ctDNA). It is hypothesized that ctDNA may identify patients who can be considered for additional therapy.
- Trial name
- NCT03746262
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Non-small Cell Lung Cancer Registry
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has…
- Trial name
- NCT00099541
- Testing
- zoledronic acid
- Where
- 101 sites in United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Small Cell Lung Cancer
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
The main aim of this study is to: evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only evaluate anti-tumor…
- Trial name
- DeLLphi-301 (NCT05060016)
- Testing
- Tarlatamab
- Where
- 80 sites in United States, Austria and 16 more
- Volunteers
- 222 people
- Sponsor
- Amgen
Non-Small-Cell Lung Cancer
Lung Cancer Information Study (LCIS-R01)
The primary specific aim is to test the hypothesis that use of a decision aid to enhance informed, shared decision making coupled with quality of life assessment in patients with advanced lung cancer receiving first-, second-, or…
- Trial name
- LCIS-R01 (NCT01924416)
- Testing
- Enhanced Care (intervention group and comparison group), Usual care (routine chemotherapy cycles and imaging studies)
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- University of Virginia
Head and Neck Neoplasms, Pheochromocytoma
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Background: The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00923481
- Testing
- Fostamatinib disodium
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer
Lung cancer is one of the most common cancer and the leading causes of cancer death in worldwide. Approximately 80% of NSCLC were inoperable. The prognosis of patients with LA-NSCLC remains disappointing.
- Trial name
- NCT02841228
- Testing
- IMRT + SIB + Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hunan Province Tumor Hospital
Dysbiosis
Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients
Lung cancer is the leading cancer in France in terms of mortality. The prognosis of the disease is closely correlated with the diagnostic stage and the majority of patients are diagnosed at a metastatic stage.
- Trial name
- ICI (NCT07191171)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Strasbourg, France
Solid Neoplasm, Stage III Pancreatic Cancer
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with…
- Conditions
- Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02897375
- Testing
- Carboplatin, Cisplatin, Palbociclib
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Emory University
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Non-small Cell Lung Cancer
To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation
This is a phase 1, open-label, dose escalation and cohort expansion study and conducted in China and the United States to investigate the safety, tolerability and preliminary efficacy of QLH11811 in advanced or metastatic NSCLC…
- Trial name
- NCT05555212
- Testing
- QLH11811
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Cancer
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00450281
- Testing
- chromogenic in situ hybridization, gene expression analysis, mutation analysis
- Where
- 405 sites in United States
- Volunteers
- 981 people
- Sponsor
- SWOG Cancer Research Network
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Non Small Cell Lung Cancer
MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Lung cancer is one of the most prevalent and lethal neoplasias in the world. Currently used chemotherapy regimens have been disappointing in improving overall survival.
- Trial name
- NCT01628471
- Testing
- decitabine in combination with genistein
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Uman Pharma
Small Cell Lung Cancer
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
To evaluate the efficacy and safety of maintenance therapy with Adebrelimab plus Apatinib for extensive stage small cell lung cancer after first-line induction of Adebrelimab plus chemotherapy.
- Trial name
- NCT06480864
- Testing
- Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 38 people
- Sponsor
- Yunpeng Liu
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT03048500
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Melanoma, Non Small Cell Lung Cancer
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
Background: The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- PragmaTIL (NCT06630611)
- Testing
- NMA-LD regimen, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Non-Small-Cell Lung Cancer
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
- Trial name
- NCT04580498
- Testing
- SHR-1701+Paclitaxel+carboplatin, SHR-1701
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Colorectal Cancer
SU006668 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer
- Trial name
- NCT00024063
- Testing
- orantinib
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer, Small Cell
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the…
- Trial name
- NCT06698965
- Testing
- Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer, Quality of Life
Supportive Care Mobile Application for Patients With NSCLC
This research study is looking at the role of a supportive care mobile app in improving symptoms, coping skills, and quality of life in patients with non-small cell lung cancer.
- Conditions
- Non Small Cell Lung Cancer, Quality of Life, Coping Skills
- Trial name
- NCT04629300
- Testing
- Supportive Care Mobile Application, Usual Care
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.